NEOVASCULAR AGE RELATED MACULAR DEGENERATION

This study tests whether people with wet age-related macular degeneration can use a home device to scan their own eyes daily, guiding when they need treatment. The goal is to see if this approach works as well as the standard schedule of regular eye injections, while possibly red…

This study tests a new drug called PRL3-zumab for people with a severe form of age-related vision loss (wet AMD) that hasn't responded to standard treatments. About 15 participants will receive either a low dose, high dose, or placebo through an IV every two weeks for three doses…

This study tests a small implant in the eye that slowly releases medication for wet age-related macular degeneration (AMD). The implant is refilled every 36 weeks, which could mean fewer doctor visits for injections. About 250 people who have already responded to standard injecti…

This study tests a new medicine called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent vision from getting worse over one year. About 800 adults aged 50 and older w…

This study tests the long-term safety of a small, refillable implant placed in the eye to deliver medication for wet age-related macular degeneration, a leading cause of vision loss. About 1000 people who have already used the implant in earlier studies will be followed for sever…

This early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants …

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older will receive either a single gene therapy injection or standard anti-VEGF shots as needed. The goal …

This study looks at how a refillable eye implant (PDS) that delivers the drug ranibizumab affects the cells on the inside of the cornea in people with wet age-related macular degeneration (nAMD). About 188 participants will receive the implant and be followed for 48 weeks. The ma…

This study will follow about 1,000 people in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see ho…

This study tests a single injection of SAR402663 into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for repeated standard treatments. About 66 adults aged 50-90 who have…

This study tests a small implant placed in the eye that releases medication every 24 weeks, compared to standard monthly eye injections. It involves 68 Chinese patients with wet age-related macular degeneration who have already responded to treatment. The goal is to see if the im…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab in real-world clinics. Researchers will track vision changes, treatment schedules, and safety over two years. The goal is …